Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting
暂无分享,去创建一个
D. Bauer | H. Genant | D. Black | E. Leblanc | E. Orwoll | D. Friess | A. Santora | A. D. de Papp | R. Dell | A. G. Rosales | D. Boardman | A. Rosales
[1] Thomas D Brown,et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] D. Solomon,et al. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta‐analysis , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] S. Silverman,et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] T. Perneger,et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. , 2012, Archives of internal medicine.
[5] J. Chandler,et al. Incidence and demography of femur fractures with and without atypical features , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] K. Michaëlsson,et al. Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.
[7] Klaus Klaushofer,et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] A. Giusti,et al. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. , 2010, Bone.
[9] J. Zerwekh,et al. Unusual mid‐shaft fractures during long‐term bisphosphonate therapy , 2010, Clinical endocrinology.
[10] M. Swiontkowski. Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2009 .
[11] D. Lorich,et al. Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.
[12] D. Lorich,et al. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. , 2008, The New England journal of medicine.
[13] T. Howe,et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? , 2008, Injury.
[14] T. Howe,et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. , 2007, The Journal of bone and joint surgery. British volume.
[15] G. Oster,et al. Compliance with osteoporosis drug therapy and risk of fracture , 2007, Osteoporosis International.
[16] S. Boonen,et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies , 2005, Osteoporosis International.
[17] E. Barrett-Connor,et al. Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] Gordon Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.
[19] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[20] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.